Biomarkers and early treatment of idiopathic pulmonary fibrosis

被引：4
作者：
Kropski, Jonathan A. [1 ,2 ,3 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37235 USA
[2] Vanderbilt Univ, Dept Cell & Dev Biol, 221 Kirkland Hall, Nashville, TN 37235 USA
[3] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA
来源：
LANCET RESPIRATORY MEDICINE | 2019年 / 7卷 / 09期
关键词：
PIRFENIDONE; NINTEDANIB; EFFICACY; LUNG;
D O I：
10.1016/S2213-2600(19)30256-5
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：725 / 727
页数：5
相关论文
共 50 条
  • [31] Nintedanib for Idiopathic Pulmonary Fibrosis
    Tepede, Abisola
    Yogaratnam, Dinesh
    JOURNAL OF PHARMACY PRACTICE, 2019, 32 (02) : 199 - 206
  • [32] New guideline on treatment of idiopathic pulmonary fibrosis
    Spagnolo, Paolo
    Bonella, Francesco
    Maher, Toby M.
    LANCET RESPIRATORY MEDICINE, 2015, 3 (09) : E31 - E32
  • [33] Current and future treatment for idiopathic pulmonary fibrosis
    Choi, Won-Il
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (04): : 256 - 263
  • [34] Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry
    Jo, Helen E.
    Glaspole, Ian
    Grainge, Christopher
    Goh, Nicole
    Hopkins, Peter M. A.
    Moodley, Yuben
    Reynolds, Paul N.
    Chapman, Sally
    Walters, E. Haydn
    Zappala, Christopher
    Allan, Heather
    Keir, Gregory J.
    Hayen, Andrew
    Cooper, Wendy A.
    Mahar, Annabelle M.
    Ellis, Samantha
    Macansh, Sacha
    Corte, Tamera J.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (02)
  • [35] Diagnosis and treatment of interstitial lung disease: focusing on idiopathic pulmonary fibrosis
    Kang, Hye-Rin
    Choi, Sun Mi
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2020, 63 (03): : 159 - 168
  • [36] Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis
    LaCamera, Peter P.
    Limb, Susan L.
    Haselkorn, Tmirah
    Morgenthien, Elizabeth A.
    Stauffer, John L.
    Wencel, Mark L.
    CHRONIC RESPIRATORY DISEASE, 2019, 16
  • [37] The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis
    Aiello, Marina
    Bertorelli, Giuseppina
    Bocchino, Marialuisa
    Chetta, Alfredo
    Fiore-Donati, Alfeo
    Fois, Alessandro
    Marinari, Stefano
    Oggionni, Tiberio
    Polla, Biagio
    Rosi, Elisabetta
    Stanziola, Anna
    Varone, Francesco
    Sanduzzi, Alessandro
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2017, 44 : 7 - 15
  • [38] A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis
    Anderson, Adam
    Shifren, Adrian
    Nathan, Steven D.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 975 - 982
  • [39] Evaluation of Proteasome Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
    Chen, I-Chen
    Liu, Yi-Ching
    Wu, Yen-Hsien
    Lo, Shih-Hsing
    Dai, Zen-Kong
    Hsu, Jong-Hau
    Tseng, Yu-Hsin
    CELLS, 2022, 11 (09)
  • [40] Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis
    Covvey, Jordan R.
    Mancl, Erin E.
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (12) : 1611 - 1619
12345